Lucid Diagnostics, Inc.

Is Lucid Diagnostics, Inc. overvalued or undervalued?

As of November 13, 2023, Lucid Diagnostics, Inc. is considered a risky investment due to its negative valuation ratios and underperformance compared to peers, despite a year-to-date return of 30.7%, which is overshadowed by a three-year decline of -42.16%.

As of 13 November 2023, the valuation grade for Lucid Diagnostics, Inc. has moved from does not qualify to risky, indicating a shift in perceived risk associated with the investment. The company appears to be overvalued given its negative valuation ratios, including a Price to Book Value of -25.96, an EV to EBIT of -3.10, and an EV to EBITDA of -3.16, all of which suggest significant financial distress.<BR><BR>In comparison to its peers, Lucid Diagnostics is underperforming, with its EV to EBITDA ratio of -2.7185 being worse than Prenetics Global Ltd.'s -1.5438, while Pro-Dex, Inc. stands out with a very attractive P/E ratio of 14.7715. The company's recent stock performance shows a year-to-date return of 30.7%, which outpaces the S&P 500's 12.22%, but this is overshadowed by a three-year decline of -42.16% compared to the S&P's 70.41% gain, reinforcing the notion that the stock may not be a sound investment at its current valuation.

Is Lucid Diagnostics, Inc. technically bullish or bearish?

As of September 9, 2025, Lucid Diagnostics, Inc. shows a mildly bearish trend with bearish daily moving averages and weekly KST, despite outperforming the S&P 500 in the past month and year-to-date, while underperforming over the last three years.

As of 9 September 2025, the technical trend for Lucid Diagnostics, Inc. has changed from sideways to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish, indicating some positive momentum. However, the daily moving averages are bearish, and the weekly KST is bearish, suggesting weakness in the short term. The Bollinger Bands show a mildly bearish stance on the weekly chart but mildly bullish on the monthly chart. The Dow Theory indicates no trend on the weekly timeframe but is mildly bullish on the monthly timeframe. <BR><BR>In terms of returns, Lucid Diagnostics has outperformed the S&P 500 over the past month (4.9% vs. 2.33%) and year-to-date (30.7% vs. 12.22%), but has significantly underperformed over the 3-year period (-42.16% vs. 70.41%). Overall, the current technical stance is mildly bearish, driven primarily by the bearish daily moving averages and the bearish weekly KST.

How big is Lucid Diagnostics, Inc.?

As of Jun 18, Lucid Diagnostics, Inc. has a market capitalization of 133.08 million, with net sales of 4.18 million and a net profit of -61.83 million over the last four quarters. The company reported shareholder's funds of 5.39 million and total assets of 30.71 million as of Dec 24.

Market Cap: As of Jun 18, Lucid Diagnostics, Inc. has a market capitalization of 133.08 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Lucid Diagnostics reported net sales of 4.18 million and a net profit of -61.83 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 5.39 million and total assets of 30.71 million.

What does Lucid Diagnostics, Inc. do?

Lucid Diagnostics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $1 million and a net loss of $27 million as of March 2025. The company has a market cap of $133.08 million and does not pay dividends.

Overview:<BR>Lucid Diagnostics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -27 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 133.08 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.57 <BR>Return on Equity: 882.48% <BR>Price to Book: -24.75<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Should I buy, sell or hold Lucid Diagnostics, Inc.?